Hematology Frontier

Chronic lymphocytic leukemia (CLL) is highly heterogeneous, with patient survival ranging from a few months to several decades. Therefore, after the diagnosis of CLL, it is particularly important to conduct an accurate and comprehensive prognostic assessment for patients. At the 2024 American Society of Hematology (ASH) Annual Meeting held from December 7th to 10th, some research results on prognostic factors of CLL were announced. "Hematology Frontier" specially invited Dr. Shenmiao Yang from the Peking University Institute of Hematology, to select key studies from the conference and provide insightful commentary, aiming to offer valuable references and insights to colleagues in the field.

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As the largest and most comprehensive international academic conference in the field of hematology, ASH attracts leading global experts to discuss groundbreaking research and advancements. This year, Dr. He Huang’s team from the Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine, had 20 studies selected for presentation, including eight as oral presentations. Their achievements not only highlighted their exceptional contributions but also delivered valuable research findings and innovative strategies to the global academic community.

The 2024 Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10 in San Diego, USA. As one of the foremost global gatherings in the field of hematology, this prestigious conference attracted the attention of clinicians and researchers worldwide, including a keen audience from China. To bring the latest and most significant updates from the conference to readers promptly, Oncology Frontier - Hematology Frontier launched a special daily column titled ASH News Broadcast · Highlights of the Day. Hosted by Dr. Jun Zhu from Peking University Cancer Hospital, the series connects with on-site experts to deliver firsthand insights. We had the privilege of speaking with Dr. Qian Jiang from Peking University People's Hospital, who shared her thoughts on the key highlights and standout presentations.

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7 to 10, 2024, in San Diego, USA. Renowned as the largest international academic event in hematology, the conference showcased cutting-edge research and the latest advancements in drug development, representing the highest academic standards in the field. At this prestigious event, Dr. Huafeng Wang’s team from The First Affiliated Hospital of Zhejiang University School of Medicine presented four impactful studies. These investigations spanned new therapeutic strategies for myelodysplastic syndrome (MDS) and insights into the mechanisms, potential treatments, and prognostic implications for acute myeloid leukemia (AML). To delve deeper into these findings, Oncology Frontier - Hematology Frontier invited Professor Wang to provide expert commentary and analysis.

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As one of the largest and most prestigious international conferences in the field of hematology, ASH highlighted groundbreaking advancements and new drug development data, showcasing the highest levels of academic research globally. Platelet delay or engraftment failure is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Strategies to accelerate platelet engraftment remain a critical clinical challenge. At this year’s ASH meeting, Dr. Erlie Jiang and his team from the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) presented findings from their study (Abstract #266) investigating the effects of elevated recombinant human thrombopoietin (rhTPO) dosing on platelet engraftment in allo-HSCT. Hematology Frontier interviewed Prof. Jiang to explore the research findings and their implications.

Acute myeloid leukemia (AML) remains a major clinical challenge due to its high heterogeneity. While CAR-T cell therapy has shown tremendous success in treating various hematologic malignancies, its application in AML is still in its infancy, necessitating further research and exploration. At the 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7–10, Dr. Mingfeng Zhao from Tianjin First Central Hospital presented groundbreaking findings on a novel iCAR-T therapy for AML, offering renewed hope for patients. Hematology Frontier had the privilege of inviting Prof. Zhao to discuss this study and share insights on his team’s future research plans.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. Among the highlights of this year’s conference were three oral presentations (Oral 94, 238, 367) focusing on CAR-T cell therapy for lymphoma. These studies showcased the latest advancements in CAR-T therapy from three perspectives: enhancing accessibility, optimizing efficacy, and addressing resistance mechanisms. Hematology Frontier invited Dr. Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth analysis of these three studies, offering valuable guidance and insights for clinical practice.

The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10, 2024, in San Diego, showcased cutting-edge advancements in hematology. Among the highlights was a study led by Dr. Peihua Lu from the Beijing Lu Daopei Hematology Hospital, presenting Phase I clinical trial results on CD7 CAR-T cell therapy for relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). In this feature, Hematology Frontier invited Professor Lu to share insights into the study's findings, the strategy for expanding CD7 CAR-T indications, and future research plans.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. At this conference, two studies by Dr. Sizhou Feng's team from the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) were included for poster presentation (P2127, P2828). "Hematology Frontier" specially invited Dr. Feng to share the research findings and their clinical significance with colleagues at the ASH venue as soon as possible.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, drawing global experts and scholars to discuss the latest advancements in hematology. In recent years, increasing insights into the pathogenesis of immune thrombocytopenia (ITP) have paved the way for innovative treatment strategies, among which SYK inhibitors have garnered significant attention due to their unique mechanisms of action. At this year’s ASH conference, Dr. Hu Zhou from Henan Cancer Hospital shared his team’s latest findings (711) on this front, offering fresh perspectives for future therapeutic strategies. Hematology Frontier invited Dr. Zhou for an in-depth discussion on his study and its clinical significance.